Document_And_Entity_Informatio
Document And Entity Information | 9 Months Ended | |
Sep. 30, 2014 | Oct. 31, 2014 | |
Document Information [Line Items] | ' | ' |
Entity Registrant Name | 'VirtualScopics, Inc. | ' |
Entity Central Index Key | '0001307752 | ' |
Current Fiscal Year End Date | '--12-31 | ' |
Entity Filer Category | 'Smaller Reporting Company | ' |
Trading Symbol | 'VSCP | ' |
Entity Common Stock, Shares Outstanding | ' | 2,994,928 |
Document Type | '10-Q | ' |
Amendment Flag | 'false | ' |
Document Period End Date | 30-Sep-14 | ' |
Document Fiscal Period Focus | 'Q3 | ' |
Document Fiscal Year Focus | '2014 | ' |
Condensed_Consolidated_Balance
Condensed Consolidated Balance Sheets (USD $) | Sep. 30, 2014 | Dec. 31, 2013 |
Current assets | ' | ' |
Cash | $5,103,190 | $7,330,630 |
Accounts receivable, net | 2,055,948 | 1,725,070 |
Prepaid expenses and other current assets | 448,909 | 397,699 |
Total current assets | 7,608,047 | 9,453,399 |
Patents, net | 1,237,137 | 1,334,420 |
Property and equipment, net | 232,665 | 221,700 |
Total assets | 9,077,849 | 11,009,519 |
Current liabilities | ' | ' |
Accounts payable and accrued expenses | 1,185,404 | 846,071 |
Accrued payroll | 796,559 | 837,611 |
Unearned revenue | 828,844 | 745,028 |
Dividends payable | 335,333 | 293,333 |
Total current liabilities | 3,146,140 | 2,722,043 |
Commitments and Contingencies | ' | ' |
Stockholders' Equity | ' | ' |
Common stock, $0.001 par value; 20,000,000 and 85,000,000 shares authorized at September 30, 2014 and December 31, 2013, respectively;issued 2,994,928 and 2,992,853 shares at September 30, 2014 and December 31, 2013, respectively; outstanding, 2,994,928 and 2,991,869 shares at September 30, 2014 and December 31, 2013, respectively | 2,995 | 2,992 |
Additional paid-in capital | 21,970,276 | 21,992,619 |
Accumulated deficit | -16,041,568 | -13,708,141 |
Total stockholders' equity | 5,931,709 | 8,287,476 |
Total liabilities and stockholders' equity | 9,077,849 | 11,009,519 |
Convertible Preferred Stock Series A [Member] | ' | ' |
Stockholders' Equity | ' | ' |
Convertible preferred stock | 2 | 2 |
Convertible Preferred Stock Series B [Member] | ' | ' |
Stockholders' Equity | ' | ' |
Convertible preferred stock | 1 | 1 |
Convertible Preferred Stock Series C - 1 [Member] | ' | ' |
Stockholders' Equity | ' | ' |
Convertible preferred stock | 3 | 3 |
Convertible Preferred Stock Series C - 2 [Member] | ' | ' |
Stockholders' Equity | ' | ' |
Convertible preferred stock | $0 | $0 |
Condensed_Consolidated_Balance1
Condensed Consolidated Balance Sheets [Parenthetical] (USD $) | Sep. 30, 2014 | Dec. 31, 2013 |
Convertible preferred stock, par value (in dollars per share) | $0.00 | $0.00 |
Convertible preferred stock, shares authorized | 1,000,000 | 15,000,000 |
Common stock, par value (in dollars per share) | $0.00 | $0.00 |
Common stock, shares authorized | 20,000,000 | 85,000,000 |
Common stock, shares issued | 2,994,928 | 2,992,853 |
Common stock, shares outstanding | 2,994,928 | 2,991,869 |
Convertible Preferred Stock Series A [Member] | ' | ' |
Convertible preferred stock, shares authorized | 8,400 | 8,400 |
Convertible preferred stock, shares issued | 2,165 | 2,190 |
Convertible preferred stock, shares outstanding | 2,165 | 2,190 |
Convertible preferred stock, liquidation preference (in dollars per share) | $1,000 | $1,000 |
Convertible Preferred Stock Series B [Member] | ' | ' |
Convertible preferred stock, shares authorized | 6,000 | 6,000 |
Convertible preferred stock, shares issued | 600 | 600 |
Convertible preferred stock, shares outstanding | 600 | 600 |
Convertible preferred stock, liquidation preference (in dollars per share) | $1,000 | $1,000 |
Convertible Preferred Stock Series C - 1 [Member] | ' | ' |
Convertible preferred stock, shares authorized | 3,000 | 3,000 |
Convertible preferred stock, shares issued | 3,000 | 3,000 |
Convertible preferred stock, shares outstanding | 3,000 | 3,000 |
Convertible preferred stock, liquidation preference (in dollars per share) | $1,000 | $1,000 |
Convertible Preferred Stock Series C - 2 [Member] | ' | ' |
Convertible preferred stock, shares authorized | 3,000 | 3,000 |
Convertible preferred stock, shares issued | 0 | 0 |
Convertible preferred stock, shares outstanding | 0 | 0 |
Convertible preferred stock, liquidation preference (in dollars per share) | $1,000 | $1,000 |
Condensed_Consolidated_Stateme
Condensed Consolidated Statements of Operations (USD $) | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2014 | Sep. 30, 2013 | Sep. 30, 2014 | Sep. 30, 2013 | |
Revenues | $2,502,413 | $2,144,535 | $7,291,415 | $7,973,973 |
Reimbursement revenues | 238,828 | 83,342 | 451,559 | 493,168 |
Total revenues | 2,741,241 | 2,227,877 | 7,742,974 | 8,467,141 |
Cost of services | 1,573,790 | 1,328,406 | 4,664,548 | 4,602,469 |
Cost of reimbursement revenues | 238,828 | 83,342 | 451,559 | 493,168 |
Total cost of services | 1,812,618 | 1,411,748 | 5,116,107 | 5,095,637 |
Gross profit | 928,623 | 816,129 | 2,626,867 | 3,371,504 |
Operating expenses | ' | ' | ' | ' |
Research and development | 307,470 | 376,595 | 899,655 | 1,179,760 |
Sales and marketing | 545,172 | 347,977 | 1,373,056 | 1,135,782 |
General and administrative | 957,795 | 753,828 | 2,452,438 | 2,526,483 |
Depreciation and amortization | 74,106 | 88,863 | 236,135 | 275,730 |
Total operating expenses | 1,884,543 | 1,567,263 | 4,961,284 | 5,117,755 |
Operating loss | -955,920 | -751,134 | -2,334,417 | -1,746,251 |
Other income (expense) | ' | ' | ' | ' |
Other income | 1,030 | 1,030 | 3,087 | 5,381 |
Other expense | -633 | -1,218 | -2,097 | 10,887 |
Total other income (expense) | 397 | -188 | 990 | 16,268 |
Net loss | -955,523 | -751,322 | -2,333,427 | -1,729,983 |
Preferred stock dividends | 42,000 | 42,000 | 126,000 | 126,000 |
Net loss available to common stockholders | ($997,523) | ($793,322) | ($2,459,427) | ($1,855,983) |
Weighted average basic and diluted shares outstanding (in shares) | 2,994,590 | 2,979,952 | 2,993,154 | 2,979,952 |
Basic and diluted loss per share (in dollars per share) | ($0.33) | ($0.27) | ($0.82) | ($0.62) |
Condensed_Consolidated_Stateme1
Condensed Consolidated Statements of Cash Flows (USD $) | 9 Months Ended | |
Sep. 30, 2014 | Sep. 30, 2013 | |
Cash flows from operating activities | ' | ' |
Net loss | ($2,333,427) | ($1,729,983) |
Adjustments to reconcile net loss to net cash used in operating activities: | ' | ' |
Depreciation and amortization | 236,135 | 275,730 |
Loss on the disposal of assets | 0 | 10,098 |
Stock-based compensation | 103,660 | 289,311 |
Changes in operating assets and liabilities | ' | ' |
Accounts receivable | -330,878 | -501,981 |
Prepaid expenses and other assets | -51,210 | 22,554 |
Accounts payable and accrued expenses | 339,333 | -199,521 |
Accrued payroll | -41,052 | 87,648 |
Unearned revenue | 83,816 | 233,034 |
Total adjustments | 339,804 | 216,873 |
Net cash used in operating activities | -1,993,623 | -1,513,110 |
Cash flows from investing activities | ' | ' |
Purchases of property and equipment | -143,793 | -26,640 |
Proceeds from the sale of equipment | 0 | 28,441 |
Patent applications and maintenance | -6,024 | -8,842 |
Net cash used in investing activities | -149,817 | -7,041 |
Cash flows from financing activities | ' | ' |
Cash dividends on series B preferred stock | -84,000 | 0 |
Net cash used in financing activities | -84,000 | 0 |
Net decrease in cash | -2,227,440 | -1,520,151 |
Cash | ' | ' |
Beginning of period | 7,330,630 | 8,523,807 |
End of period | 5,103,190 | 7,003,656 |
Non-cash financing activity: | ' | ' |
Accrued dividends on series B and C-1 preferred stock | 42,000 | 251,333 |
Series A Preferred Stock [Member] | ' | ' |
Non-cash financing activity: | ' | ' |
Conversion of series A preferred stock into common stock | $2 | $0 |
Nature_of_Business_and_Basis_o
Nature of Business and Basis of Presentation | 9 Months Ended |
Sep. 30, 2014 | |
Organization and Basis Of Presentation [Abstract] | ' |
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] | ' |
NOTE 1 - Nature of Business and Basis of Presentation | |
Nature of Business | |
The headquarters of VirtualScopics. Inc. and its wholly-owned subsidiary, VirtualScopics, LLC (the “Subsidiary” and, together, the “Company”) are located in Rochester, New York. The Company has created a suite of image analysis software tools and applications which are used in detecting and measuring specific anatomical structures and metabolic activity using medical images. The Company’s developed proprietary software provides measurement capabilities designed to improve pharmaceutical and medical device research and development and improve clinical medical image analysis. | |
Basis of Presentation | |
The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information pursuant to article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for condensed financial statements and should be read in conjunction with the audited consolidated financial statements and notes related thereto contained in the Company’s Annual Report on Form 10-K as of and for the year ended December 31, 2013. In the opinion of management, these financial statements contain all adjustments necessary for a fair presentation for and as of the end of the interim period, all of which were normal recurring adjustments. The results of operations for the three and nine months ended September 30, 2014 are not necessarily indicative of the results to be expected for the full year ending December 31, 2014. | |
A Certificate of Amendment to decrease the Company’s number of authorized common stock from 85,000,000 shares to 20,000,000 shares and to decrease the number of authorized and undesignated preferred stock from 15,000,000 shares to 1,000,000 shares was approved by the Company's stockholders at its Annual Meeting of Stockholders held on June 17, 2014. The authorized share information presented in these financial statements and accompanying footnotes reflects such change. | |
Summary_of_Certain_Significant
Summary of Certain Significant Accounting Policies | 9 Months Ended |
Sep. 30, 2014 | |
Accounting Policies [Abstract] | ' |
Significant Accounting Policies [Text Block] | ' |
NOTE 2 - Summary of Certain Significant Accounting Policies | |
Principles of Consolidation | |
The accompanying condensed consolidated financial statements include the accounts of the Company and the Subsidiary. All significant intercompany balances and transactions have been eliminated in consolidation. | |
Revenue Recognition | |
The Company recognizes revenue when it is realized or realizable and earned. The Company considers revenue realized or realizable and earned when an agreement exists, services and products have been performed or delivered, as the case may be, prices are fixed or determinable, and collectability is reasonably assured. Revenues are reduced for estimated discounts and other allowances, if any. | |
The Company provides advanced medical image analysis on a per analysis basis, and recognizes revenue when the image analysis is completed. Revenue related to project, data and site management services is recognized as the services are rendered and in accordance with the terms of the contract. Consulting revenue is recognized once the services are rendered and typically charged at an hourly rate. | |
Occasionally, the Company has provided software development services to its customers, which may require development, modification, and customization. Software development revenue is billed on a fixed price basis and recognized upon delivery of the software and acceptance by the customer on a completed contract basis. The Company does not sell software licenses, upgrades or enhancements, or post-contract customer services. | |
Reimbursements received and related costs incurred for out-of-pocket expenses are separately reported as revenue and cost of services, respectively, in the financial statements. | |
Income Taxes | |
In its interim financial statements, the Company follows the guidance of Accounting Standards Codification (“ASC”) 270 “Interim Reporting” and ASC 740 “Income Taxes” whereby it uses the expected annual effective tax rate in determining its interim tax provisions. Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized based upon the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases, and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income and the reversal of deferred tax liabilities during the period in which related temporary differences become deductible. The benefit of tax positions taken or expected to be taken in the Company’s income tax returns are recognized in the consolidated financial statements if such positions are more likely than not of being sustained. | |
Research and Development | |
Research and development expense relates to the development of new applications and processes including improvements and enhancements to existing software applications. These costs are expensed as incurred. | |
Reclassifications | |
The Company has reclassified certain amounts from its previously reported condensed consolidated financial statements for comparative purposes to conform to the fiscal 2014 presentation. These reclassifications had no impact on the Company’s previously reported condensed consolidated results from operations or cash flows. | |
Recent Accounting Pronouncements | |
The Financial Accounting Standards Board (“FASB”) has issued Accounting Standards Update (“ASU”) No. 2014-12, Compensation – Stock Compensation (Topic 718): Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period. This ASU requires that a performance target that affects vesting, and that could be achieved after the requisite service period, be treated as a performance condition. As such, the performance target should not be reflected in estimating the grant date fair value of the award. This update further clarifies that compensation cost should be recognized in the period in which it becomes probable that the performance target will be achieved and should represent the compensation cost attributable to the period(s) for which the requisite service has already been rendered. The amendments in this ASU are effective for annual periods and interim periods within those annual periods beginning after December 15, 2015. Earlier adoption is permitted. The adoption of this standard is not expected to have a material impact on the Company’s condensed consolidated financial position and results of operations. | |
The FASB has issued ASU No. 2014-09, Revenue from Contracts with Customers. This ASU supersedes the revenue recognition requirements in Accounting Standards Codification 605 - Revenue Recognition and most industry-specific guidance throughout the Codification. The standard requires that an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. This ASU is effective on January 1, 2017 and should be applied retrospectively to each prior reporting period presented or retrospectively with the cumulative effect of initially applying the ASU recognized at the date of initial application. The adoption of this standard is not expected to have a material impact on the Company’s condensed consolidated financial position and results of operations. | |
StockBased_Compensation
Stock-Based Compensation | 9 Months Ended | |||||||||||||
Sep. 30, 2014 | ||||||||||||||
Disclosure Of Compensation Related Costs, Share-Based Payments [Abstract] | ' | |||||||||||||
Disclosure of Compensation Related Costs, Share-based Payments [Text Block] | ' | |||||||||||||
NOTE 3 - Stock-Based Compensation | ||||||||||||||
For the three and nine months ended September 30, 2014 and 2013, the Company’s condensed consolidated statements of operations reflect stock-based compensation expense for stock options granted under its long-term incentive plans and allocated as follows: | ||||||||||||||
Three Months Ended | Nine Months Ended | |||||||||||||
September 30, | September 30, | |||||||||||||
2014 | 2013 | 2014 | 2013 | |||||||||||
Cost of service revenues | $ | 10,052 | $ | 12,909 | $ | 30,316 | $ | 38,123 | ||||||
Research and development | 7,680 | 12,392 | 26,165 | 48,288 | ||||||||||
Sales and marketing | 2,290 | 2,789 | 7,026 | 8,612 | ||||||||||
General and administrative | 19,020 | 1,487 | 39,595 | 174,509 | ||||||||||
Total stock-based compensation | $ | 39,042 | $ | 29,577 | $ | 103,102 | $ | 269,532 | ||||||
Stock options issued under the Company’s long-term incentive plans are granted with an exercise price equal but no less than the market price of the Company’s stock at the date of grant and expire up to ten years from the date of grant. These options generally vest over a three or four-year period. As of September 30, 2014, there was $388,589 of total unrecognized compensation cost related to non-vested share-based compensation arrangements. This cost is expected to be recognized over a weighted-average period of 3.24 years. | ||||||||||||||
The fair value of stock options granted was determined on the grant date using assumptions for risk free interest rate, the expected term, expected volatility, and expected dividend yield. The risk free interest rate is based on U.S. Treasury zero-coupon yield curve over the expected term of the option. The expected term assumption is determined using the weighted average midpoint between the vesting and expiration term for all individuals within the grant. The Company estimated its expected volatility using its own historical stock prices. The Company’s model includes a zero dividend yield assumption, as the Company has not historically paid nor does it anticipate paying dividends on its common stock. The Company’s model does not include a discount for post-vesting restrictions, as the Company has not issued awards with such restrictions. The periodic expense is then determined based on the valuation of the options, and at that time an estimated forfeiture rate is used to reduce the expense recorded. The Company’s estimate of pre-vesting forfeitures is primarily based on the Company’s historical experience and is adjusted to reflect actual forfeitures as the options vest. The following assumptions were used to estimate the fair value of options granted for the nine months ended September 30, 2014 and 2013 using the Black-Scholes option-pricing model: | ||||||||||||||
September 30, | ||||||||||||||
2014 | 2013 | |||||||||||||
Risk free interest rate | 1.8 | % | 1.5 | % | ||||||||||
Expected term (years) | 5.9 | 6.6 | ||||||||||||
Expected volatility | 64.6 | % | 71.3 | % | ||||||||||
Expected dividend yield | - | - | ||||||||||||
A summary of the employee stock option activity for the nine months ended september 30, 2014 is as follows: | ||||||||||||||
Number of | Weighted | Weighted | ||||||||||||
Shares | Average | Average | ||||||||||||
Exercise | Remaining | |||||||||||||
Price | Contractual | |||||||||||||
Term | ||||||||||||||
Options outstanding at January 1, 2014 | 425,875 | $ | 12.72 | |||||||||||
Granted | 177,517 | 4.14 | ||||||||||||
Exercised | - | |||||||||||||
Cancelled/Forfeited | -201,280 | -10.23 | ||||||||||||
Expired | -316 | -23.6 | ||||||||||||
Options outstanding at September 30, 2014 | 401796 | 10.17 | 6.42 | |||||||||||
Options exercisable at September 30, 2014 | 206,503 | 15.04 | 3.57 | |||||||||||
As of September 30, 2014 and 2013, the Company had options outstanding to consultants of 0 and 520, respectively. | ||||||||||||||
The weighted-average grant-date fair value of options granted during the nine months ended September 30, 2014 and 2013 was $434,438 and $8,687, respectively. | ||||||||||||||
Stockholders_Equity
Stockholders' Equity | 9 Months Ended | |||||||
Sep. 30, 2014 | ||||||||
Stockholders Equity Note [Abstract] | ' | |||||||
Stockholders' Equity Note Disclosure [Text Block] | ' | |||||||
NOTE 4 - Stockholders’ Equity | ||||||||
As of September 30, 2014, the Company has authorized 1,000,000 shares of preferred stock, par value $0.001 per share, of which 8,400 are designated as Series A Convertible Preferred Stock (“Series A”), 6,000 are designated as Series B Convertible Preferred Stock (“Series B”), 3,000 are designated as Series C-1 Convertible Preferred Stock (“Series C-1”), and 3,000 are designated as Series C-2 Convertible Preferred Stock (“Series C-2”) as specified in the Certificate of Designation (the “Certificate”). During the nine months ended September 30, 2014, there were 25 shares of Series A Preferred Stock converted to 2,075 shares of common stock and there were no conversions of the Series A Preferred Stock during the nine months ended September 30, 2013,.Additionally there were no conversions of the Company’s convertible Series B and C-1 preferred stock during the nine months ended September 30, 2014 and 2013. | ||||||||
Each share of Series A is convertible into 83.036 shares of the Company’s common stock and is senior in liquidation preference in comparison to shares of the Company’s common stock. | ||||||||
Each share of Series B is convertible into 83.036 shares of the Company’s common stock and has a liquidation preference that is pari passu with the Company’s Series A and senior to the Company’s common stock. Cumulative dividends on the Series B accrue on the stated value of $1,000 per share at an annual rate of 8%, payable monthly in cash and/or shares of the Company’s common stock at the option of the Company. Subject to certain exceptions, the Series B holders are only entitled to be paid dividends if full dividends are first paid or concurrently paid to the holders of the Series C-1. As of September 30, 2014 and December 31, 2013, there were $96,000 and $84,000, respectively of accrued dividends payable to Series B stockholders. During the nine months ended September 30, 2014 and 2013, cash dividends paid to Series B stockholders aggregated to $24,000 and $0, respectively. | ||||||||
Each share of Series C-1 is convertible into shares of the Company’s common stock at a conversion rate determined by dividing (i) the stated value per share of $1,000, plus, if consented to by the Company, all accrued and unpaid dividends, by (ii) the conversion price of $12.043. The Series C-1 is senior in liquidation preference in comparison to shares of the Company’s common stock and the Series A and Series B preferred stock. Cumulative dividends on the Series C accrue on the stated value of $1,000 per share at an annual rate of 4%. As of September 30, 2014 and December 31, 2013, there were $239,333 and $209,333, respectively of accrued dividends payable to Series C-1 stockholders. During the nine months ended September 30, 2014 and 2013, cash dividends paid to Series C-1 stockholders aggregated to $60,000 and $0, respectively. | ||||||||
Restricted Stock Awards | ||||||||
A restricted stock award entitles the recipient to receive shares of unrestricted common stock upon vesting of the award and expiration of certain restrictions contained in the grant of such award. The fair value of each restricted stock award is determined upon granting of the shares and the related compensation expense is recognized ratably over the vesting period and charged to the operations as non-cash compensation expense. Shares contained in the unvested portion of restricted stock awards are forfeited upon termination of employment, unless otherwise agreed. The fair value of restricted stock issued under the Plan is determined based on the closing price of the Company’s common stock on the grant date. | ||||||||
A summary of the restricted stock award activity for the nine months ended September 30, 2014 is as follows: | ||||||||
Number | Weighted | |||||||
of Units | Average | |||||||
Grant | ||||||||
Date Fair | ||||||||
Value | ||||||||
Nonvested at January 1, 2014 | 984 | 7.4 | ||||||
Granted | - | - | ||||||
Vested | -984 | -7.4 | ||||||
Cancelled/Forfeited | - | - | ||||||
Nonvested at September 30, 2014 | - | - | ||||||
The Company incurred $558 and $19,779 in compensation expense during the nine months ended September 30, 2014 and 2013, respectively, and $0 and $7,427 in compensation expense during the three months ended September 30, 2014 and 2013, respectively, related to the restricted stock awards granted to Board members and former officers of the Company. During the nine months ended September 30, 2014, 984 restricted stock units vested as part of the former CFO’s consulting agreement. | ||||||||
Loss_Per_Share
Loss Per Share | 9 Months Ended | |||||
Sep. 30, 2014 | ||||||
Earnings Per Share [Abstract] | ' | |||||
Earnings Per Share [Text Block] | ' | |||||
NOTE 5 – Loss Per Share | ||||||
Basic earnings and loss per share are computed by dividing the net income or loss available to common stockholders by the weighted average number of common shares outstanding during the period. Diluted earnings per share is computed using the weighted average number of common shares and, if dilutive, potential common shares outstanding during the period. Potential common shares consist of the incremental common shares issuable upon the exercise of stock options (using the treasury stock method) and the conversion of the Company’s convertible preferred stock and warrants (using the if-converted method). Diluted loss per share excludes the shares issuable upon the conversion of preferred stock, the exercise of stock options and warrants from the calculation of net loss per share as their effect would be antidilutive. | ||||||
Securities that could potentially dilute earnings per share in the future that were not included in the computation of diluted loss per share consist of the following numbers of shares into which preferred stock could have been converted and shares for which outstanding options and warrants could have been exercised during the three and nine months ending September 30, 2014 and 2013: | ||||||
2014 | 2013 | |||||
Convertible preferred stock | 478,701 | 480,777 | ||||
Warrants to purchase common stock | 136,132 | 233,753 | ||||
Non-vested restricted stock awards | - | 12,796 | ||||
Options to purchase common stock | 401,796 | 554,898 | ||||
Total | 1,016,629 | 1,282,404 | ||||
Income_Taxes
Income Taxes | 9 Months Ended |
Sep. 30, 2014 | |
Income Tax Disclosure [Abstract] | ' |
Income Tax Disclosure [Text Block] | ' |
NOTE 6 - Income Taxes | |
The Company has significant net operating loss and business credit carryovers which are subject to a valuation allowance due to the uncertain nature of the realization of the losses. The Internal Revenue Code imposes certain limitations on the utilization of net operating loss carryovers and other tax attributes after a change in control. The Company does not believe it has encountered ownership changes which could significantly limit the possible utilization of such carryovers. It is not anticipated that limitations, if any, would have a material impact on the condensed consolidated balance sheet as a result of offsetting changes in the deferred tax valuation allowance. Based on all available evidence, the Company believes that its deferred tax assets should be fully reserved as of September 30, 2014 because it is still currently more likely than not that the benefits of the Company’s deferred tax assets will not be realized in future periods. The Company will continue to assess the likelihood of recognizing a portion of its deferred tax assets and will make an assessment of whether it should reduce the valuation allowance. | |
The Company will recognize interest and penalties accrued related to unrecognized tax benefits as components of its income tax provision. As of September 30, 2014, the Company does not have any interest and penalties accrued related to unrecognized tax benefits. | |
Concentration_of_Credit_Risk
Concentration of Credit Risk | 9 Months Ended |
Sep. 30, 2014 | |
Risks and Uncertainties [Abstract] | ' |
Concentration Risk Disclosure [Text Block] | ' |
NOTE 7 - Concentration of Credit Risk | |
The Company’s top four customers accounted for approximately 28%, 22%, 19%, and 10% of total revenue for the nine months ended September 30, 2014. Three customers accounted for 45%, 11%, and 11% of total revenue for the nine months ended September 30, 2013. | |
The Company’s top three customers accounted for approximately 25%, 24%, and 22% of total revenue for the three months ended September 30, 2014. Three customers accounted for 36%, 16%, and 14% of total revenue for the three months ended September 30, 2013. | |
Three customers accounted for approximately 30%, 23%, and 17% of accounts receivable as of September 30, 2014. Four customers accounted for approximately 34%, 13%, 13%, and 11% of accounts receivable as of December 31, 2013. | |
Related_Party
Related Party | 9 Months Ended |
Sep. 30, 2014 | |
Related Party Transactions [Abstract] | ' |
Related Party Transactions Disclosure [Text Block] | ' |
NOTE 8 – Related Party | |
In April 2012, the Company issued Merck Global Health Innovation Fund, LLC (“Merck”) 3,000 shares of Series C-1 which are convertible into 249,107 shares of common stock and Series C-1 Warrants which are exercisable to purchase 136,132 shares of common stock. . Revenues generated from Merck were $88,932 and $164,171 for the nine months ended September 30, 2014 and 2013, respectively and $46,177 and $34,736 for the three months ended September 30, 2014 and 2013, respectively. The accounts receivable balance due from Merck was $32,118 and $87,200 as of September 30, 2014 and December 31, 2013, respectively. | |
Commitments_and_Contingencies
Commitments and Contingencies | 9 Months Ended |
Sep. 30, 2014 | |
Commitments and Contingencies Disclosure [Abstract] | ' |
Commitments and Contingencies Disclosure [Text Block] | ' |
NOTE 9 – Commitments and Contingencies | |
Operating Lease | |
In May 2014, the Company entered into a lease for approximately 2,190 square feet of office space in New Hope, Pennsylvania. The lease term is for three years with a lease commencement date of September 1, 2014. The base annual rent under the lease is $54,000, and increases three percent (3%) per year over the term of the lease. | |
Employment Agreements | |
On July 23, 2014, (the “Effective Date”), the Company entered into an employment agreement with Eric T. Converse who was appointed President and Chief Executive Officer (the “CEO Employment Agreement”). The CEO Employment Agreement begins as of the Effective Date, has an initial term of one year and will be extended automatically for one-year periods so long as Mr. Converse remains fully employed by the Company. Mr. Converse will receive an annual salary of $325,000 during the term of the CEO Employment Agreement. Mr. Converse is also eligible to receive an annual incentive bonus tied to the achievement of Company goals approved by the Compensation Committee of the Company’s Board of Directors. On the Effective Date, Mr. Converse was also granted an option to purchase 87,017 shares of the Company’s common stock with a $4.22 exercise price, four year vesting period, and ten year term. If Mr. Converse remains employed by the Company on the date that is twelve months after the Effective Date, the Company will award an option to purchase an additional 87,017 shares, and if employed twenty-four months after the Effective Date, then the Company will also award an option to purchase an additional 43,510 shares. Each award is subject to the terms of the Company’s Amended and Restated 2006 Long-Term Incentive Plan. The options will vest at the rate of 25% on each anniversary of each award while Mr. Converse is employed by the Company. | |
The CEO Employment Agreement provides that if the Company terminates Mr. Converse’s employment without cause, then the Company is required to pay his annual salary and benefits for a period of six months. If a change in control (as defined in the CEO Employment Agreement) occurs on or before the third anniversary of the Effective Date, then the Company is required to pay Mr. Converse an amount equal to 75% of his annual salary for the year in which the change in control occurs. | |
On August 19, 2014 (the “Second Effective Date”), the Company entered into an employment agreement with James A. Groff, pursuant to which Mr. Groff agreed to serve as the Company’s Chief Financial Officer (the “CFO Employment Agreement”). The term of the CFO Employment Agreement begins as of the Second Effective Date, and will be extended automatically for one-year periods so long as Mr. Groff remains fully employed by the Company. Mr. Groff will receive an annual salary of $150,000 during the term of the CFO Employment Agreement. Mr. Groff is also eligible to receive an annual incentive bonus tied to the achievement of Company goals approved by the Compensation Committee of the Company’s Board of Directors. On the Second Effective Date, Mr. Groff was granted an option to purchase 25,000 shares of the Company’s common stock. If Mr. Groff remains employed by the Company on the date that is twelve months after the Second Effective Date, the Company will award an option to purchase an additional 25,000 shares, and if employed twenty-four months after the Second Effective Date, then the Company will also award an option to purchase an additional 25,000 shares. Each award is subject to the terms of the Company’s Amended and Restated 2006 Long-Term Incentive Plan. The options will vest at the rate of 25% on each anniversary of each award while Mr. Groff is employed by the Company. | |
The CFO Employment Agreement provides that if the Company terminates Mr. Groff’s employment without cause, then the Company is required to pay his annual salary and benefits for a period of six months. If a change in control (as defined in the CFO Employment Agreement) occurs on or before the third anniversary of the Second Effective Date, then the Company is required to pay Mr. Groff an amount equal to 50% of his annual salary for the year in which the change in control occurs. | |
Subsequent_Events
Subsequent Events | 9 Months Ended |
Sep. 30, 2014 | |
Subsequent Events [Abstract] | ' |
Subsequent Events [Text Block] | ' |
NOTE 10 - Subsequent Events | |
The Company evaluates events that have occurred after the balance sheet date but before the financial statements are issued. Based upon the evaluation, the Company did not identify any recognized or non-recognized subsequent events that would have required adjustment or disclosure in the condensed consolidated financial statements. | |
Summary_of_Certain_Significant1
Summary of Certain Significant Accounting Policies (Policies) | 9 Months Ended |
Sep. 30, 2014 | |
Accounting Policies [Abstract] | ' |
Consolidation, Policy [Policy Text Block] | ' |
Principles of Consolidation | |
The accompanying condensed consolidated financial statements include the accounts of the Company and the Subsidiary. All significant intercompany balances and transactions have been eliminated in consolidation. | |
Revenue Recognition, Policy [Policy Text Block] | ' |
Revenue Recognition | |
The Company recognizes revenue when it is realized or realizable and earned. The Company considers revenue realized or realizable and earned when an agreement exists, services and products have been performed or delivered, as the case may be, prices are fixed or determinable, and collectability is reasonably assured. Revenues are reduced for estimated discounts and other allowances, if any. | |
The Company provides advanced medical image analysis on a per analysis basis, and recognizes revenue when the image analysis is completed. Revenue related to project, data and site management services is recognized as the services are rendered and in accordance with the terms of the contract. Consulting revenue is recognized once the services are rendered and typically charged at an hourly rate. | |
Occasionally, the Company has provided software development services to its customers, which may require development, modification, and customization. Software development revenue is billed on a fixed price basis and recognized upon delivery of the software and acceptance by the customer on a completed contract basis. The Company does not sell software licenses, upgrades or enhancements, or post-contract customer services. | |
Reimbursements received and related costs incurred for out-of-pocket expenses are separately reported as revenue and cost of services, respectively, in the financial statements. | |
Income Tax, Policy [Policy Text Block] | ' |
Income Taxes | |
In its interim financial statements, the Company follows the guidance of Accounting Standards Codification (“ASC”) 270 “Interim Reporting” and ASC 740 “Income Taxes” whereby it uses the expected annual effective tax rate in determining its interim tax provisions. Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized based upon the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases, and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income and the reversal of deferred tax liabilities during the period in which related temporary differences become deductible. The benefit of tax positions taken or expected to be taken in the Company’s income tax returns are recognized in the consolidated financial statements if such positions are more likely than not of being sustained. | |
Research and Development Expense, Policy [Policy Text Block] | ' |
Research and Development | |
Research and development expense relates to the development of new applications and processes including improvements and enhancements to existing software applications. These costs are expensed as incurred. | |
Reclassification, Policy [Policy Text Block] | ' |
Reclassifications | |
The Company has reclassified certain amounts from its previously reported condensed consolidated financial statements for comparative purposes to conform to the fiscal 2014 presentation. These reclassifications had no impact on the Company’s previously reported condensed consolidated results from operations or cash flows. | |
New Accounting Pronouncements, Policy [Policy Text Block] | ' |
Recent Accounting Pronouncements | |
The Financial Accounting Standards Board (“FASB”) has issued Accounting Standards Update (“ASU”) No. 2014-12, Compensation – Stock Compensation (Topic 718): Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period. This ASU requires that a performance target that affects vesting, and that could be achieved after the requisite service period, be treated as a performance condition. As such, the performance target should not be reflected in estimating the grant date fair value of the award. This update further clarifies that compensation cost should be recognized in the period in which it becomes probable that the performance target will be achieved and should represent the compensation cost attributable to the period(s) for which the requisite service has already been rendered. The amendments in this ASU are effective for annual periods and interim periods within those annual periods beginning after December 15, 2015. Earlier adoption is permitted. The adoption of this standard is not expected to have a material impact on the Company’s condensed consolidated financial position and results of operations. | |
The FASB has issued ASU No. 2014-09, Revenue from Contracts with Customers. This ASU supersedes the revenue recognition requirements in Accounting Standards Codification 605 - Revenue Recognition and most industry-specific guidance throughout the Codification. The standard requires that an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. This ASU is effective on January 1, 2017 and should be applied retrospectively to each prior reporting period presented or retrospectively with the cumulative effect of initially applying the ASU recognized at the date of initial application. The adoption of this standard is not expected to have a material impact on the Company’s condensed consolidated financial position and results of operations. | |
StockBased_Compensation_Tables
Stock-Based Compensation (Tables) | 9 Months Ended | |||||||||||||
Sep. 30, 2014 | ||||||||||||||
Disclosure Of Compensation Related Costs, Share-Based Payments [Abstract] | ' | |||||||||||||
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block] | ' | |||||||||||||
For the three and nine months ended September 30, 2014 and 2013, the Company’s condensed consolidated statements of operations reflect stock-based compensation expense for stock options granted under its long-term incentive plans and allocated as follows: | ||||||||||||||
Three Months Ended | Nine Months Ended | |||||||||||||
September 30, | September 30, | |||||||||||||
2014 | 2013 | 2014 | 2013 | |||||||||||
Cost of service revenues | $ | 10,052 | $ | 12,909 | $ | 30,316 | $ | 38,123 | ||||||
Research and development | 7,680 | 12,392 | 26,165 | 48,288 | ||||||||||
Sales and marketing | 2,290 | 2,789 | 7,026 | 8,612 | ||||||||||
General and administrative | 19,020 | 1,487 | 39,595 | 174,509 | ||||||||||
Total stock-based compensation | $ | 39,042 | $ | 29,577 | $ | 103,102 | $ | 269,532 | ||||||
Schedule of Share-based Compensation, Activity [Table Text Block] | ' | |||||||||||||
The following assumptions were used to estimate the fair value of options granted for the nine months ended September 30, 2014 and 2013 using the Black-Scholes option-pricing model: | ||||||||||||||
September 30, | ||||||||||||||
2014 | 2013 | |||||||||||||
Risk free interest rate | 1.8 | % | 1.5 | % | ||||||||||
Expected term (years) | 5.9 | 6.6 | ||||||||||||
Expected volatility | 64.6 | % | 71.3 | % | ||||||||||
Expected dividend yield | - | - | ||||||||||||
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block] | ' | |||||||||||||
A summary of the employee stock option activity for the nine months ended september 30, 2014 is as follows: | ||||||||||||||
Number of | Weighted | Weighted | ||||||||||||
Shares | Average | Average | ||||||||||||
Exercise | Remaining | |||||||||||||
Price | Contractual | |||||||||||||
Term | ||||||||||||||
Options outstanding at January 1, 2014 | 425,875 | $ | 12.72 | |||||||||||
Granted | 177,517 | 4.14 | ||||||||||||
Exercised | - | |||||||||||||
Cancelled/Forfeited | -201,280 | -10.23 | ||||||||||||
Expired | -316 | -23.6 | ||||||||||||
Options outstanding at September 30, 2014 | 401796 | 10.17 | 6.42 | |||||||||||
Options exercisable at September 30, 2014 | 206,503 | 15.04 | 3.57 | |||||||||||
Stockholders_Equity_Tables
Stockholders' Equity (Tables) | 9 Months Ended | |||||||
Sep. 30, 2014 | ||||||||
Disclosure Of Compensation Related Costs, Share-Based Payments [Abstract] | ' | |||||||
Schedule Of Share Based Compensation Non Vested Stock Options Activity [Table Text Block] | ' | |||||||
A summary of the restricted stock award activity for the nine months ended September 30, 2014 is as follows: | ||||||||
Number | Weighted | |||||||
of Units | Average | |||||||
Grant | ||||||||
Date Fair | ||||||||
Value | ||||||||
Nonvested at January 1, 2014 | 984 | 7.4 | ||||||
Granted | - | - | ||||||
Vested | -984 | -7.4 | ||||||
Cancelled/Forfeited | - | - | ||||||
Nonvested at September 30, 2014 | - | - | ||||||
Loss_Per_Share_Tables
Loss Per Share (Tables) | 9 Months Ended | |||||
Sep. 30, 2014 | ||||||
Earnings Per Share [Abstract] | ' | |||||
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] | ' | |||||
Securities that could potentially dilute earnings per share in the future that were not included in the computation of diluted loss per share consist of the following numbers of shares into which preferred stock could have been converted and shares for which outstanding options and warrants could have been exercised during the three and nine months ending September 30, 2014 and 2013: | ||||||
2014 | 2013 | |||||
Convertible preferred stock | 478,701 | 480,777 | ||||
Warrants to purchase common stock | 136,132 | 233,753 | ||||
Non-vested restricted stock awards | - | 12,796 | ||||
Options to purchase common stock | 401,796 | 554,898 | ||||
Total | 1,016,629 | 1,282,404 | ||||
Nature_of_Business_and_Basis_o1
Nature of Business and Basis of Presentation (Details Textual) | Sep. 30, 2014 | Dec. 31, 2013 |
Common Stock, Shares Authorized | 20,000,000 | 85,000,000 |
Preferred Stock, Shares Authorized | 1,000,000 | 15,000,000 |
StockBased_Compensation_Detail
Stock-Based Compensation (Details) (USD $) | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2014 | Sep. 30, 2013 | Sep. 30, 2014 | Sep. 30, 2013 | |
Stock-based compensation | $39,042 | $29,577 | $103,102 | $269,532 |
Cost of service revenues [Member] | ' | ' | ' | ' |
Stock-based compensation | 10,052 | 12,909 | 30,316 | 38,123 |
Research and development [Member] | ' | ' | ' | ' |
Stock-based compensation | 7,680 | 12,392 | 26,165 | 48,288 |
Sales and marketing [Member] | ' | ' | ' | ' |
Stock-based compensation | 2,290 | 2,789 | 7,026 | 8,612 |
General and administrative [Member] | ' | ' | ' | ' |
Stock-based compensation | $19,020 | $1,487 | $39,595 | $174,509 |
StockBased_Compensation_Detail1
Stock-Based Compensation (Details 1) | 9 Months Ended | |
Sep. 30, 2014 | Sep. 30, 2013 | |
Risk free interest rate | 1.80% | 1.50% |
Expected term (years) | '5 years 10 months 24 days | '6 years 7 months 6 days |
Expected volatility | 64.60% | 71.30% |
Expected dividend yield | 0.00% | 0.00% |
StockBased_Compensation_Detail2
Stock-Based Compensation (Details 2) (USD $) | 9 Months Ended |
Sep. 30, 2014 | |
Options outstanding - Number of Shares at January 1, 2014 | 425,875 |
Granted - Number of Shares | 177,517 |
Exercised - Number of Shares | 0 |
Cancelled/Forfeited - Number of Shares | -201,280 |
Expired - Number of Shares | -316 |
Options outstanding - Number of Shares at September 30, 2014 | 401,796 |
Options exercisable - Number of Shares at September 30, 2014 | 206,503 |
Beginning balance, Options outstanding - Weighted Average Exercise Price | $12.72 |
Granted - Weighted Average Exercise Price | $4.14 |
Cancelled/Forfeited - Weighted Average Exercise Price | ($10.23) |
Expired - Weighted Average Exercise Price | ($23.60) |
Ending balance, Options outstanding - Weighted Average Exercise Price | $10.17 |
Options exercisable - Weighted Average Exercise Price | $15.04 |
Options outstanding - Weighted Average Remaining Life (Years) | '6 years 5 months 1 day |
Options exercisable - Weighted Average Remaining Contractual Term (in years) | '3 years 6 months 25 days |
StockBased_Compensation_Detail3
Stock-Based Compensation (Details Textual) (USD $) | 9 Months Ended | ||
Sep. 30, 2014 | Sep. 30, 2013 | Dec. 31, 2013 | |
Share Based Compensation Options Grants In Period Weighted Average Grant Date Fair Value | $434,438 | $8,687 | ' |
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Total | $388,589 | ' | ' |
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition | '3 years 2 months 26 days | ' | ' |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Beginning Balance | 401,796 | ' | 425,875 |
Consultant [Member] | ' | ' | ' |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Beginning Balance | 0 | 520 | ' |
Stockholders_Equity_Details
Stockholders' Equity (Details) (USD $) | 9 Months Ended |
Sep. 30, 2014 | |
Nonvested, Number of Units | 984 |
Granted, Number of Units | 0 |
Vested, Number of Units | -984 |
Cancelled/Forfeited, Number of Units | 0 |
Nonvested, Number of Units | 0 |
Weighted Average Grant Date Fair Value, NonVested (in dollars per share) | $7.40 |
Weighted Average Grant Date Fair Value, Vested (in dollars per share) | ($7.40) |
Stockholders_Equity_Details_Te
Stockholders' Equity (Details Textual) (USD $) | 3 Months Ended | 9 Months Ended | |||
Sep. 30, 2014 | Sep. 30, 2013 | Sep. 30, 2014 | Sep. 30, 2013 | Dec. 31, 2013 | |
Convertible preferred stock, shares authorized | 1,000,000 | ' | 1,000,000 | ' | 15,000,000 |
Preferred Stock, Par or Stated Value Per Share | $0.00 | ' | $0.00 | ' | $0.00 |
Cash dividends on preferred stock | ' | ' | $84,000 | $0 | ' |
Stock-based compensation | 39,042 | 29,577 | 103,102 | 269,532 | ' |
Series A Preferred Stock [Member] | ' | ' | ' | ' | ' |
Convertible Preferred Stock, Shares Issued upon Conversion | 2,075 | ' | 2,075 | ' | ' |
Conversion of Stock, Shares Converted | ' | ' | 25 | ' | ' |
Chief Financial Officer [Member] | ' | ' | ' | ' | ' |
Stock Issued During Period, Shares, Restricted Stock Award, Gross | ' | ' | 984 | ' | ' |
Restricted Stock Units (RSUs) [Member] | ' | ' | ' | ' | ' |
Stock-based compensation | 0 | 7,427 | 558 | 19,779 | ' |
Series A Convertible Preferred Stock [Member] | ' | ' | ' | ' | ' |
Preferred Stock Designated During Period Shares | ' | ' | 8,400 | ' | ' |
Stock Conversion Ratio | ' | ' | 83.036 | ' | ' |
Series C-1 Convertible Preferred Stock [Member] | ' | ' | ' | ' | ' |
Preferred Stock Designated During Period Shares | ' | ' | 3,000 | ' | ' |
Preferred Stock, Liquidation Preference Per Share | $1,000 | ' | $1,000 | ' | ' |
Preferred Stock Conversion Price Per Share | $12.04 | ' | $12.04 | ' | ' |
Interest and Dividends Payable, Total | 239,333 | ' | 239,333 | ' | 209,333 |
Cash dividends on preferred stock | ' | ' | 60,000 | 0 | ' |
Preferred Stock, Dividend Rate, Percentage | ' | ' | 4.00% | ' | ' |
Series C-2 Convertible Preferred Stock [Member] | ' | ' | ' | ' | ' |
Convertible preferred stock, shares authorized | 3,000 | ' | 3,000 | ' | 3,000 |
Preferred Stock Designated During Period Shares | ' | ' | 3,000 | ' | ' |
Preferred Stock, Liquidation Preference Per Share | $1,000 | ' | $1,000 | ' | $1,000 |
Series B Convertible Preferred Stock [Member] | ' | ' | ' | ' | ' |
Preferred Stock Designated During Period Shares | ' | ' | 6,000 | ' | ' |
Preferred Stock, Liquidation Preference Per Share | $1,000 | ' | $1,000 | ' | ' |
Interest and Dividends Payable, Total | 96,000 | ' | 96,000 | ' | 84,000 |
Stock Conversion Ratio | ' | ' | 83.036 | ' | ' |
Annual Dividend Rate | ' | ' | 8.00% | ' | ' |
Cash dividends on preferred stock | ' | ' | $24,000 | $0 | ' |
Loss_Per_Share_Details
Loss Per Share (Details) | 3 Months Ended | 9 Months Ended |
Sep. 30, 2014 | Sep. 30, 2013 | |
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | 1,016,629 | 1,282,404 |
Convertible Debt Securities [Member] | ' | ' |
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | 478,701 | 480,777 |
Restricted Stock [Member] | ' | ' |
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | 0 | 12,796 |
Warrant [Member] | ' | ' |
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | 136,132 | 233,753 |
Employee Stock Option [Member] | ' | ' |
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | 401,796 | 554,898 |
Concentration_of_Credit_Risk_D
Concentration of Credit Risk (Details Textual) | 3 Months Ended | 9 Months Ended | |||
Sep. 30, 2014 | Sep. 30, 2013 | Sep. 30, 2014 | Sep. 30, 2013 | Dec. 31, 2013 | |
Customer 1 [Member] | ' | ' | ' | ' | ' |
Entity-Wide Accounts Receivable, Major Customer, Percentage | 30.00% | ' | 30.00% | ' | 34.00% |
Concentration Risk, Percentage | 25.00% | 36.00% | 28.00% | 45.00% | ' |
Customer 2 [Member] | ' | ' | ' | ' | ' |
Entity-Wide Accounts Receivable, Major Customer, Percentage | 23.00% | ' | 23.00% | ' | 13.00% |
Concentration Risk, Percentage | 24.00% | 16.00% | 22.00% | 11.00% | ' |
Customer 3 [Member] | ' | ' | ' | ' | ' |
Entity-Wide Accounts Receivable, Major Customer, Percentage | ' | ' | ' | ' | 13.00% |
Concentration Risk, Percentage | ' | 14.00% | 19.00% | 11.00% | ' |
Customer 4 [Member] | ' | ' | ' | ' | ' |
Entity-Wide Accounts Receivable, Major Customer, Percentage | 17.00% | ' | 17.00% | ' | 11.00% |
Concentration Risk, Percentage | 22.00% | ' | 10.00% | ' | ' |
Related_Party_Details_Textual
Related Party (Details Textual) (USD $) | 1 Months Ended | 3 Months Ended | 9 Months Ended | |||
Apr. 30, 2012 | Sep. 30, 2014 | Sep. 30, 2013 | Sep. 30, 2014 | Sep. 30, 2013 | Dec. 31, 2013 | |
Common stock issuable upon conversion of preferred stock | 249,107 | ' | ' | ' | ' | ' |
Revenue from Related Parties | ' | $46,177 | $34,736 | $88,932 | $164,171 | ' |
Accounts Receivable, Related Parties | ' | $32,118 | ' | $32,118 | ' | $87,200 |
Series C-1 Preferred Stock [Member] | ' | ' | ' | ' | ' | ' |
Preferred Stock and Warrant Purchase Agreement Shares Issued | 3,000 | ' | ' | ' | ' | ' |
Series C-1 Warrants [Member] | ' | ' | ' | ' | ' | ' |
Preferred Stock and Warrant Purchase Agreement, Warrants Issued To Acquire Common Stock Shares, Number | 136,132 | ' | ' | ' | ' | ' |
Commitments_and_Contingencies_
Commitments and Contingencies (Details Textual) (USD $) | 1 Months Ended | 9 Months Ended | 1 Months Ended | |||||
31-May-14 | Sep. 30, 2014 | Jul. 23, 2014 | Jul. 23, 2014 | Jul. 23, 2014 | Aug. 19, 2014 | Aug. 19, 2014 | Aug. 19, 2014 | |
Chief Executive Officer [Member] | Chief Executive Officer [Member] | Chief Executive Officer [Member] | Chief Financial Officer [Member] | Chief Financial Officer [Member] | Chief Financial Officer [Member] | |||
Twelve months after the Effective Date [Member] | Twenty-four months after the Effective Date [Member] | Twelve months after the Effective Date [Member] | Twenty-four months after the Effective Date [Member] | |||||
Leasing Space Square Feet | '2,190 | ' | ' | ' | ' | ' | ' | ' |
Base Annual Rent | ' | $54,000 | ' | ' | ' | ' | ' | ' |
Rent Increased Percentage | ' | 3.00% | ' | ' | ' | ' | ' | ' |
Officers' Compensation | ' | ' | $325,000 | ' | ' | $150,000 | ' | ' |
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage | ' | ' | 25.00% | ' | ' | 25.00% | ' | ' |
Share-based Compensation Arrangement by Share-based Payment Award, Per Share Weighted Average Price of Shares Purchased | ' | ' | $4.22 | ' | ' | ' | ' | ' |
Share-based Compensation Arrangement by Share-based Payment Award, Shares Purchased for Award | ' | ' | 87,017 | ' | ' | 25,000 | ' | ' |
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized | ' | ' | ' | 87,017 | 43,510 | ' | 25,000 | 25,000 |
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period | ' | ' | '4 years | ' | ' | ' | ' | ' |
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period | ' | ' | '10 years | ' | ' | ' | ' | ' |
Deferred Compensation Arrangement with Individual, Cash Awards Granted, Percentage | ' | ' | 75.00% | ' | ' | 50.00% | ' | ' |